In 2016, the FDA approved the first drug, Nusinersen, as an anti-sense oligonucleotide (ASO) treatment of SMA, which increases SMN expression through alternative splicing of SMN2 pre-mRNA. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.